A drug to fight Covid even better. Unveiling the news of the Anakinra is Matteo Bassetti, director of the infectious disease clinic of the San Martino Polyclinic in Genoa, who acts as the spokesperson in Italy for the Italian-Greek study “Save more” coordinated by Evangelos Giamarellos-Bourboulis, Professor of Internal Medicine and Infectious Diseases at the National University of Koper in Athens: “600 patients hospitalized for Covid, therefore a severe form of the disease, were enrolled. Anakinra, this potent inflammation inhibitor, was used, and the results say it reduces the mortality and aggressiveness of the infection. So it is one more weapon among our possible weapons to use. The dossier has been submitted to the EMA and we all hope that it will be approved in the coming weeks so that it can be used together with other drugs. It is a drug that enhances the effect of cortisone when there is a lot of inflammation “.
“The drug Anakinra – continues Bassetti in the interview with primocanale – reduces mortality from severe pneumonia. Early and targeted use of the drug, in addition to current standards of care, reduces mortality and progression towards severe respiratory failure and increases also the number of patients discharged from hospital in the absence of Covid infection. Anakinra is a drug for rheumatoid arthritis, a powerful anti-inflammatory that according to research can improve overall clinical results by 64% “.
The infectious disease specialist then revealed that a new study will start next week, the one in which Molnupiravir will be tested: “We will finally start with the famous pill only in non-hospitalized subjects so we go to work on those who have Covid without serious symptoms He is at home”. “This could be the use in the future, who has a positive swab, who has mild symptoms, takes this tablet and turns off the infection in the bud, we can say – concludes Bassetti – that it is a kind of oral monoclonal”.